Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-01-27 10:07 am Sale | 2024-12-31 | 13G | Cellectar Biosciences, Inc. CLRB | Orin Hirschman | 2,022,221 4.900% | -640,103 (-24.04%) | Filing History |
| 2024-11-14 4:53 pm Purchase | 2024-09-30 | 13G | Cellectar Biosciences, Inc. CLRB | Nantahala Capital Management LLC | 3,677,739 9.990% | 447,836 (+13.87%) | Filing History |
| 2024-11-14 4:47 pm Purchase | 2024-09-30 | 13G | Cellectar Biosciences, Inc. CLRB | ADAR1 Capital Management LLC | 3,684,708 8.510% | 3,684,708 (New Position) | Filing History |
| 2024-11-14 1:26 pm Purchase | 2024-09-30 | 13G | Cellectar Biosciences, Inc. CLRB | Lytton, Laurence W. | 4,389,969 9.990% | 1,109,791 (+33.83%) | Filing History |
| 2024-08-14 7:15 pm Purchase | 2024-07-25 | 13G | Cellectar Biosciences, Inc. CLRB | Rosalind Advisors, Inc. | 6,970,425 9.900% | 2,977,839 (+74.58%) | Filing History |
| 2024-07-11 5:37 pm Unchanged | 2024-06-28 | 13G | Cellectar Biosciences, Inc. CLRB | Rosalind Advisors, Inc. | 3,992,586 9.900% | 0 (Unchanged) | Filing History |
| 2024-04-25 8:01 pm Sale | 2024-03-31 | 13G | Cellectar Biosciences, Inc. CLRB | Rosalind Advisors, Inc. | 3,992,586 9.900% | -2,684,347 (-40.20%) | Filing History |
| 2024-02-14 8:31 pm Purchase | 2023-12-31 | 13G | Cellectar Biosciences, Inc. CLRB | Rosalind Advisors, Inc. | 6,676,933 9.900% | 4,518,661 (+209.36%) | Filing History |
| 2024-02-14 4:51 pm Purchase | 2023-12-31 | 13G | Cellectar Biosciences, Inc. CLRB | Nantahala Capital Management LLC | 3,229,903 9.900% | 3,229,903 (New Position) | Filing History |
| 2024-02-14 4:29 pm Purchase | 2023-12-31 | 13G | Cellectar Biosciences, Inc. CLRB | Lincoln Park Capital Fund LLC | 1,307,049 9.676% | 369,461 (+39.41%) | Filing History |
| 2024-02-14 3:23 pm Purchase | 2023-12-31 | 13G | Cellectar Biosciences, Inc. CLRB | Lytton, Laurence W. | 3,280,178 9.990% | 1,395,105 (+74.01%) | Filing History |
| 2024-02-07 6:58 pm Purchase | 2024-01-23 | 13G | Cellectar Biosciences, Inc. CLRB | Orin Hirschman | 2,662,324 8.700% | 747,104 (+39.01%) | Filing History |
| 2024-01-31 08:00 am Purchase | 2024-01-23 | 13G | Cellectar Biosciences, Inc. CLRB | ADAR1 Partners LP | 1,824,063 6.210% | 1,824,063 (New Position) | Filing History |
| 2023-12-07 5:15 pm Purchase | 2023-10-25 | 13G | Cellectar Biosciences, Inc. CLRB | Lytton, Laurence W. | 1,885,073 9.990% | 1,885,073 (New Position) | Filing History |
| 2023-12-05 06:01 am Purchase | 2023-11-07 | 13G | Cellectar Biosciences, Inc. CLRB | Orin Hirschman | 1,915,220 9.900% | 1,915,220 (New Position) | Filing History |
| 2023-02-13 5:53 pm Unchanged | 2022-12-31 | 13G | Cellectar Biosciences, Inc. CLRB | Rosalind Advisors, Inc. | 2,158,272 9.970% | 0 (Unchanged) | Filing History |
| 2023-02-13 3:14 pm Purchase | 2022-12-31 | 13G | Cellectar Biosciences, Inc. CLRB | Lytton, Laurence W. | 482,430 4.990% | 64,651 (+15.47%) | Filing History |
| 2022-11-02 8:03 pm Purchase | 2022-10-25 | 13G | Cellectar Biosciences, Inc. CLRB | Rosalind Advisors, Inc. | 2,158,272 9.970% | 1,553,044 (+256.60%) | Filing History |
| 2022-10-25 06:01 am Purchase | 2022-10-21 | 13G | Cellectar Biosciences, Inc. CLRB | Lincoln Park Capital Fund LLC | 937,588 9.990% | 706,220 (+305.24%) | Filing History |
| 2022-02-14 7:44 pm Sale | 2021-12-31 | 13G | Cellectar Biosciences, Inc. CLRB | Lytton, Laurence W. | 417,779 6.600% | -56,621 (-11.94%) | Filing History |